Toggle navigation
Browse
Home
Researchers
Research Departments
Publications
About/Support
Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study.
Meeting Abstract
International Collaboration
Overview
Research
Additional Document Info
View All
Overview
cited authors
Pal, Sumanta Kumar; Grivas, Petros; Gupta, Shilpa; Valderrama, Begona Perez; Rodriguez-Vida, Alejo; Roghmann, Florian; Sevillano, Elena; Matin, Surena F.; Loriot, Yohann; Sridhar, Srikala S.; Sonpavde, Guru P.; Fleming, Mark T.; Lerner, Seth P.; Bellmunt, Joaquim; Master, Viraj A.; Tripathi, Abhishek; Davis, Kim; Van Veenhuyzen, David Friedrich; Weng, Richard; Daneshmand, Siamak
Publication Date
February 1, 2024
webpage
Web of Science
published in
JOURNAL OF CLINICAL ONCOLOGY
Journal
Research
category
ONCOLOGY
Web of Science Category
keywords
2
261-376
261-492-199-2823
261-492-3532-2370-7650-2454-5112
261-492-3532-2370-7650-2700
3
3229
38092-20390
38092-23141
4
613-225-313
Additional Document Info
start page
629
end page
629
volume
42
issue
4_SUPPL